Supernus Pharmaceuticals Files 8-K on Financials
Ticker: SUPN · Form: 8-K · Filed: Jul 22, 2025 · CIK: 1356576
| Field | Detail |
|---|---|
| Company | Supernus Pharmaceuticals, Inc. (SUPN) |
| Form Type | 8-K |
| Filed Date | Jul 22, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, sec-filing, operations
Related Tickers: SUPN
TL;DR
SUPN filed an 8-K on 7/22/25 with financial results and exhibits.
AI Summary
On July 22, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report detailing its results of operations and financial condition. The filing includes financial statements and exhibits, providing an update on the company's financial performance. The report was filed with the SEC under the 1934 Act.
Why It Matters
This filing provides investors with crucial, up-to-date financial information and operational results for Supernus Pharmaceuticals, Inc., enabling informed investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any unusual events or significant changes.
Key Numbers
- 001-35518 — SEC File Number (Identifies the company's filing history)
- 20-2590184 — I.R.S. Employer Identification No. (Tax identification for the company)
Key Players & Entities
- Supernus Pharmaceuticals, Inc. (company) — Registrant
- July 22, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Rockville, MD (location) — Principal Executive Offices
- 1934 Act (regulation) — SEC Act
FAQ
What specific financial statements are included in this 8-K filing?
The filing indicates that financial statements and exhibits are included, but the specific details of these statements are not enumerated in the provided text.
What is the primary purpose of this 8-K filing for Supernus Pharmaceuticals, Inc.?
The primary purpose is to report on the company's Results of Operations and Financial Condition as of July 22, 2025.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the principal executive office address for Supernus Pharmaceuticals, Inc.?
The principal executive offices are located at 9715 Key West Ave, Rockville, MD 20850.
Does this filing indicate any changes to the company's name or address since the last report?
The filing mentions 'Not Applicable' for former name or former address, if changed since last report, suggesting no recent changes were reported in this section.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 22, 2025 regarding SUPERNUS PHARMACEUTICALS, INC. (SUPN).